Iliad founder and shareholder Dr Bernard Flynn will join Bionomics
when the acquisition is completed.
has achieved several milestones in its CNS development program in 2004, with the successful worldwide licensing of its diagnostic test for a form of severe childhood epilepsy, now marketed in the US, and the securing of strategic Australian and international collaborations in drug discovery.
Bernhard Kirschbaum, Executive Vice President Research at Merck Serono, said "This partnership with Bionomics
reflects our long-term commitment to patients with MS as Kv1.
will hold Bionomics
' growing intellectual property interests in the United States and will provide enhanced access for Bionomics
to United States government grant funding.
Athena has also expressed interest in licensing other epilepsy tests that Bionomics
may develop in the future.
Their experience in the utilization of novel imaging techniques to serve as biomarkers and history of partnering with regulatory agencies to develop standards for imaging acquisition, data normalization, data extraction and the assessment of variability made the selection of ACR Image Metrix as our imaging CRO appropriate for this project," stated Bionomics
Vice President of Discovery Research, Gabriel Kremmidiotis, Ph.
The Louisiana State University Health Sciences Center (Shreveport, LA) and Bionomics
Limited (Adelaide, Australia) announced that they have finalized an agreement for collaborative study of a Bionomics
proprietary gene that shows promise for treating cancer.
occidentalis has been intensively studied, little information on the bionomics
of less pestiferous Frankliniella species is available.
Seven of Australia's leading research organisations together with Cancer Research Technology Limited based in London (UK), Bionomics
Limited (Australia), and Millipore/Chemicon (Australia), today announced they were finalising negotiations for the formation of the Cooperative Research Centre for Cancer Therapeutics (CRC-CT).
Andrew Brooks, Director of the Bionomics
Research and Technology Center at the University of Medicine and Dentistry of New Jersey.
ADELAIDE, Australia, April 10, 2015 /PRNewswire/ -- Bionomics
Limited ( ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7[sup.
Presenting companies include Agenix Limited (ASX:AGX), Peptech Limited (ASX:PTD), Bionomics
Limited (ASX:BNO, US OTC:BMICY), Biota Holdings (ASX:BTA), Uscom (ASX:UCM), Medical Therapies (ASX:MTY), Proteome Systems (ASX:PTL), SingVax Pte Ltd, Singapore, and S*Bio Pte Ltd, Singapore.